MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199

Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocat...

Full description

Bibliographic Details
Main Authors:	Benito, J, Godfrey, L, Kojima, K, Hogdal, L, Wunderlich, M, Geng, H, Marzo, I, Harutyunyan, K, Golfman, L, North, P, Kerry, J, Ballabio, E, Chonghaile, T, Gonzalo, O, Qiu, Y, Jeremias, I, Debose, L, O'Brien, E, Ma, H, Zhou, P, Jacamo, R, Park, E, Coombes, K, Zhang, N, Thomas, D, O'Brien, S, Kantarjian, H, Leverson, J, Kornblau, S, Andreeff, M, Müschen, M, Zweidler-McKay, P, Mulloy, J, Letai, A, Milne, T, Konopleva, M
Format:	Journal article
Language:	English
Published:	Cell Press 2015

MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199

Similar Items